Uric Acid in vitro diagnostic test REF: 31H0P
FDA Device Recall #Z-2086-2026 — Class II — April 2, 2026
Recall Summary
| Recall Number | Z-2086-2026 |
| Classification | Class II — Moderate risk |
| Date Initiated | April 2, 2026 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | DFI Co., Ltd. |
| Location | Gimhae |
| Product Type | Devices |
| Quantity | 59815 units |
Product Description
Uric Acid in vitro diagnostic test REF: 31H0P
Reason for Recall
The devices were distributed without required FDA premarket clearance or approval.
Distribution Pattern
Worldwide - US Nationwide distribution in the states of FL, PA and the country of England.
Lot / Code Information
UDI: 08806141303077/ Lot: 241023, 250415, 250509, 250617, 250905
Other Recalls from DFI Co., Ltd.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-2087-2026 | Class II | One Step K in vitro diagnostic test REF: 81A4 | Apr 2, 2026 |
| Z-2085-2026 | Class II | QUCARE Total Cholesterol in vitro diagnostic te... | Apr 2, 2026 |
| Z-2088-2026 | Class II | One Step P in vitro diagnostic test REF: 8194 | Apr 2, 2026 |
| Z-2084-2026 | Class II | One Step pH in vitro diagnostic test REF: 31I4P | Apr 2, 2026 |
| Z-2082-2026 | Class II | One Step 10A in vitro diagnostic test | Apr 2, 2026 |
Frequently Asked Questions
Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.